Delaware
|
001-35068
|
41-2193603
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
25821 Industrial Boulevard, Suite 400
Hayward, CA
|
94545
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on
which registered |
||
Common Stock, $0.001 par value
|
ACRX
|
The Nasdaq Global Market
|
Emerging growth company ☐
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
2,089,366,469
|
989,274,832
|
383,282
|
--
|
ACELRX PHARMACEUTICALS, INC.
|
||
Dated: September 23, 2022
|
By:
|
/s/ Raffi Asadorian
|
Name:
|
Raffi Asadorian
|
|
Title:
|
Chief Financial Officer
|